Diagnosis, Management, and Prognosis of Liver Diseases
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Diagnosis and Prognosis".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 16
Special Issue Editor
2. College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Interests: chemoembolization; portal vein; chronic liver failure; liver disease; viral hepatitis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The prompt and accurate diagnosis, management, and prognostication of acute and chronic liver diseases, including viral hepatitis, cirrhosis, portal hypertension, hepatic encephalopathy, sarcopenia, acute-on-chronic liver failure (ACLF), and hepatocellular carcinoma (HCC), are of paramount importance. Emerging biomarkers for the functional cure of hepatitis B virus (HBV), such as quantitative hepatitis B surface antigen (qHBsAg), hepatitis B core-related antigen (HBcrAg), and HBV RNA, together with liquid biopsy and immune biomarkers for HCC, are increasingly important in clinical practice and translational research. In addition, cirrhosis-associated immune dysfunction syndrome (CAIDS), frailty, gut microbiome alterations, and extrahepatic manifestations of liver disease have become increasingly recognized as important determinants of patient outcomes.
Delayed or inaccurate diagnosis and treatment of liver disease and its related syndromes can lead to substantial morbidity and mortality. For example, the early diagnosis of HBV flare through the identification of elevated alanine aminotransferase (ALT) and HBV DNA, followed by prompt antiviral therapy, can reduce the risk of severe hepatitis flare, hepatic decompensation, and HBV-related ACLF. Likewise, prompt diagnostic paracentesis combined with appropriate antibiotic therapy can reduce in-hospital mortality in patients with suspected spontaneous bacterial peritonitis. Furthermore, accurate prognostic tools can help identify patients at high risk of poor outcomes or treatment futility, such as patients with ACLF and high CLIF-C ACLF scores (≥70), who may reach the threshold at which ongoing intensive support is unlikely to provide meaningful benefit.
This Special Issue welcomes submissions addressing all aspects of the diagnosis, management, and prognosis of acute and chronic liver diseases and their associated syndromes. Topics of interest include novel biomarkers, non-invasive tests, artificial intelligence-based prediction models, radiomics, liquid biopsy, multi-omics approaches, and precision medicine strategies. We also encourage submissions on monitoring tools for emerging therapies, including resmetirom, semaglutide, tirzepatide, glucagon-like peptide-1 receptor agonists, and combination treatment strategies for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Examples of novel biomarkers include fibrosis-4 (FIB-4), enhanced liver fibrosis (ELF) score, Mac-2 binding protein glycosylation isomer (M2BPGi), liver stiffness measurement by transient elastography, neutrophil-to-lymphocyte ratio (NLR), proteomics and metabolomics signatures, and artificial intelligence-based prediction tools for steatosis, fibrosis, HCC, and clinical outcomes in liver disease.
We look forward to receiving your contributions.
Dr. Chien Hao Huang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute liver disease
- chronic liver disease
- viral hepatitis
- liver cirrhosis
- metabolic dysfunction-associated steatotic liver disease (MASLD)
- metabolic dysfunction-associated steatohepatitis (MASH)
- hepatocellular carcinoma
- biomarkers
- artificial intelligence
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
